Inside the 7th mRNA Roundtable: Building the mRNA Ecosystem in Cambridge with Crystal NAX
7th mRNA Roundtable by Crystal NAX brought together 40+ leaders from biotech, pharma, and VC in Cambridge to discuss the rapid evolution of mRNA platforms, targeted delivery, manufacturability, and translational development.
Cas9 Delivery Formats Compared: mRNA, RNP, Plasmid, and AAV
Choosing a Cas9 delivery format is one of the earliest decisions in a gene editing program. This guide compares plasmid DNA, AAV, RNP, and mRNA across expression kinetics, integration risk, primary cell compatibility, and regulatory strategy.
Regulatory Expectations for dsRNA Control in RNA Therapeutics in 2026
In 2026, the FDA and the EMA do not define a universal threshold for dsRNA in RNA therapeutics. This guide covers FDA vs EMA expectations, analytical validation, and dsRNA comparability requirements.
MediciBIO and Crystal NAX Partner for RNA LNP Platform and Products
MediciBIO Co., Ltd. and Crystal NAX (NAX) Inc have entered into a partnership agreement for the integration of MediciBIO’s lipid nanoparticle (LNP) platform into NAX’s global service offering, and the appointment of MediciBIO as NAX’s authorized distributor for the South Korean market.
ASGCT 2026: In Vivo Cell Engineering and the Next RNA & LNP Wave
Crystal NAX scientists report the latest advancements on RNA and LNP therapeutics seen on ASGCT 2026 in Boston: in vivo CAR-T, LNP-based delivery and alternative payload formats including circRNA and ssDNA.
Crystal NAX joins Scientist.com as a supplier
Crystal NAX supports custom mRNA synthesis with m1Ψ modification, high-throughput LNP formulation screening, targeted LNP conjugation, and analytical characterization covering particle attributes, encapsulation efficiency, and dsRNA impurity profiling.
Inside the 7th mRNA Roundtable: Building the mRNA Ecosystem in Cambridge with Crystal NAX
7th mRNA Roundtable by Crystal NAX brought together 40+ leaders from biotech, pharma, and VC in Cambridge to discuss the rapid evolution of mRNA platforms, targeted delivery, manufacturability, and translational development.
MediciBIO and Crystal NAX Partner for RNA LNP Platform and Products
MediciBIO Co., Ltd. and Crystal NAX (NAX) Inc have entered into a partnership agreement for the integration of MediciBIO’s lipid nanoparticle (LNP) platform into NAX’s global service offering, and the appointment of MediciBIO as NAX’s authorized distributor for the South Korean market.
ASGCT 2026: In Vivo Cell Engineering and the Next RNA & LNP Wave
Crystal NAX scientists report the latest advancements on RNA and LNP therapeutics seen on ASGCT 2026 in Boston: in vivo CAR-T, LNP-based delivery and alternative payload formats including circRNA and ssDNA.
Crystal NAX joins Scientist.com as a supplier
Crystal NAX supports custom mRNA synthesis with m1Ψ modification, high-throughput LNP formulation screening, targeted LNP conjugation, and analytical characterization covering particle attributes, encapsulation efficiency, and dsRNA impurity profiling.
Join our San Diego Biotech Networking Event: RNA and LNP
Join Crystal NAX in this San Diego biotech networking event focused on RNA CMC, LNP delivery, and development strategy.
CPHI Frankfurt 2025: Crystal NAX Showcase with the Crystal Pharmatech Group
Discover the advancements presented at CPHI Frankfurt 2025, where Crystal NAX showcased with the Crystal Pharmatech family. This event highlighted our innovative capabilities in nucleic acid therapeutics, including RNA design, synthesis, and delivery technologies.
Cas9 Delivery Formats Compared: mRNA, RNP, Plasmid, and AAV
Choosing a Cas9 delivery format is one of the earliest decisions in a gene editing program. This guide compares plasmid DNA, AAV, RNP, and mRNA across expression kinetics, integration risk, primary cell compatibility, and regulatory strategy.
Regulatory Expectations for dsRNA Control in RNA Therapeutics in 2026
In 2026, the FDA and the EMA do not define a universal threshold for dsRNA in RNA therapeutics. This guide covers FDA vs EMA expectations, analytical validation, and dsRNA comparability requirements.
DNA and RNA Delivery Methods for Gene Therapy Compared
A technical comparison of DNA and RNA gene therapy delivery systems, covering viral vectors, lipid nanoparticles, and non-viral platforms.
Targeted LNP formulation: Antibodies, Aptamers, and Peptides
Ligand choice for targeted LNP shapes more than biology. It determines LNP formulation, immune profile, and analytical burden. Here is how the three main classes compare.
How to Choose the Best Cas9 mRNA for Gene Editing
The best Cas9 mRNA for gene editing is defined by transcript integrity, dsRNA content, capping efficiency, nucleotide modification strategy, and functional validation in a cell-based potency assay. This guide explains what how to evaluate batch data, for researchers working proof of concept to early IND-enabling studies.
How Double-Stranded RNA (dsRNA) Jeopardize RNA Therapeutics
Double-stranded RNA (dsRNA) is an intrinsic IVT impurity that activates immune responses, suppresses translation, and must be controlled within CMC strategy for RNA therapeutics.